article · Scientific Reports
Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge, underscoring the need for antiviral strategies that extend beyond conventional small-molecule inhibitors. Here, we investigate the cyanobacterial phycobiliprotein allophycocyanin (APC) as a natural macromolecular scaffold with combined antiviral and antioxidant activities. Integrative protein-protein docking and long-timescale molecular dynamics simulations revealed stable APC interactions with HIV-1 gp120, protease, and reverse transcriptase (RT), with gp120 displaying the most favorable binding propensity based on qualitative free-energy ranking and interfacial stability. Isothermal titration calorimetry demonstrated a moderate, enthalpy-driven gp120-APC interaction in solution, consistent with a transient yet biologically relevant protein-protein association. In HIV-1-infected cells, APC treatment reduced viral protein abundance, including gp120, protease, and RT, and significantly inhibited RT enzymatic activity. APC also mitigated infection-induced oxidative stress, restoring redox balance toward basal levels. While computational affinity estimates are semi-quantitative and cellular uptake mechanisms were not directly examined, the combined structural, biophysical, and cellular data support a model in which APC interferes with viral entry and downstream replication while providing host-protective antioxidant effects. Collectively, this study advances APC from a general antioxidant biomolecule to a mechanistically characterized natural macromolecular inhibitor with potential relevance as an adjunctive anti-HIV-1 strategy.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1038/s41598-026-44038-x
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.